Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma - PubMed (original) (raw)
Clinical Trial
. 2002 Jan 1;99(1):67-74.
doi: 10.1182/blood.v99.1.67.
Affiliations
- PMID: 11756154
- DOI: 10.1182/blood.v99.1.67
Free article
Clinical Trial
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
Stephen M Ansell et al. Blood. 2002.
Free article
Abstract
Rituximab is a chimeric murine/human monoclonal antibody that binds to CD20 on B lymphocytes. Although binding of the Fab domain may induce apoptosis, the Fc domain recruits immune effector functions to mediate cell lysis. Interleukin-12 (IL-12) facilitates cytolytic T-cell responses, enhances the lytic activity of natural killer (NK) cells, and induces the secretion of interferon gamma (IFN-gamma) by both T and NK cells. Therefore, the hypothesis was considered that combining IL-12 with rituximab would augment the immune-mediated cell lysis induced by rituximab. A phase 1 study of IL-12 in combination with rituximab was conducted in 43 adults with B-cell lymphoma to determine the optimal immunologic dose of this combination. Rituximab was administered at a dose of 375 mg/m(2) by intravenous infusion weekly for 4 weeks, and IL-12 was given subcutaneously twice weekly. The starting dose of IL-12 was 30 ng/kg and this was escalated to 500 ng/kg. Constitutional symptoms and liver enzyme elevations at 500 ng/kg of IL-12 were dose limiting. A greater than 20-fold increase in the serum levels of IFN-gamma and a 2.5- to 5-fold increase in inducible protein 10 (IP-10) levels was seen at IL-12 doses of 100 ng/kg or greater. Objective responses occurred in 29 of the 43 patients (69%), with 8 of 11 complete responses seen at IL-12 doses of 300 ng/kg or greater. The optimal immunologic dose of IL-12 in combination with rituximab was determined to be 300 ng/kg subcutaneously twice weekly starting on day 2. These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted.
Similar articles
- Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE. Ansell SM, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6056-63. doi: 10.1158/1078-0432.CCR-06-1245. Clin Cancer Res. 2006. PMID: 17062681 Clinical Trial. - Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M. Gluck WL, et al. Clin Cancer Res. 2004 Apr 1;10(7):2253-64. doi: 10.1158/1078-0432.ccr-1087-3. Clin Cancer Res. 2004. PMID: 15073100 Clinical Trial. - Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Eisenbeis CF, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6101-10. doi: 10.1158/1078-0432.CCR-04-0525. Clin Cancer Res. 2004. PMID: 15447996 Clinical Trial. - [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K. Tobinai K. Nihon Rinsho. 2002 Jan;60(1):95-9. Nihon Rinsho. 2002. PMID: 11808346 Review. Japanese.
Cited by
- Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Tedder TF, Baras A, Xiu Y. Tedder TF, et al. Springer Semin Immunopathol. 2006 Dec;28(4):351-64. doi: 10.1007/s00281-006-0057-9. Epub 2006 Nov 8. Springer Semin Immunopathol. 2006. PMID: 17091246 - Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas.
Mitsuhashi M, Liu J, Cao S, Shi X, Ma X. Mitsuhashi M, et al. J Leukoc Biol. 2004 Aug;76(2):322-32. doi: 10.1189/jlb.1203641. Epub 2004 May 3. J Leukoc Biol. 2004. PMID: 15123779 Free PMC article. Review. - Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Lacy MQ, et al. Leuk Res. 2009 Nov;33(11):1485-9. doi: 10.1016/j.leukres.2009.01.020. Epub 2009 Feb 24. Leuk Res. 2009. PMID: 19243818 Free PMC article. Clinical Trial. - Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Portielje JE, Kruit WH, Eerenberg AJ, Schuler M, Sparreboom A, Lamers CH, Gratama JW, Stoter G, Huber C, Hack CE. Portielje JE, et al. Cancer Immunol Immunother. 2005 Jan;54(1):37-43. doi: 10.1007/s00262-004-0574-0. Cancer Immunol Immunother. 2005. PMID: 15693137 Free PMC article. - Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.
Nadal L, Peissert F, Elsayed A, Weiss T, Look T, Weller M, Piro G, Carbone C, Tortora G, Matasci M, Favalli N, Corbellari R, Di Nitto C, Prodi E, Libbra C, Galeazzi S, Carotenuto C, Halin C, Puca E, Neri D, De Luca R. Nadal L, et al. J Immunother Cancer. 2022 Sep;10(9):e005282. doi: 10.1136/jitc-2022-005282. J Immunother Cancer. 2022. PMID: 36104101 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources